Johnson & Johnson Vision: Surgical Vision Announces New Data and Sustainability Activities at European Society of Cataract and Refractive Surgeons Congress
- More than 30 abstracts will be presented across a range of Johnson & Johnson Vision equipment and IOLs including: TECNIS Synergy™ IOL, TECNIS Eyhance™ IOL and VERITAS™ Vision System
- Supporting ESCRS’ Mission Zero target through ongoing sustainability efforts
- Participating in I-Novation sessions on Sustainability, Presbyopia and Cataract Extraction & the
I-Novation European Leadership Panel
- Hosting inaugural ‘Women in Ophthalmology’ networking and mentorship session
London – 15 September 2022 – Johnson & Johnson Vision: Surgical Vision*, a global leader in eye health and part of Johnson & Johnson MedTech*, will be presenting new data and participating in a series of events at the upcoming 40th European Society of Cataract and Refractive Surgeons (ESCRS) congress 16-20 September 2022. The congress, taking place at the Milano Convention Centre in Milan, Italy, will showcase a range of breakthrough data, with over 30 abstracts supported by Johnson & Johnson Vision accepted for presentation throughout the congress.
The Johnson & Johnson Vision ESCRS Booth (#A02/B01) will have live demonstration areas for surgeons to experience first-hand the VERITAS™ Vision System, a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety by providing improved anterior chamber stability during the procedure,1,2 surgeon efficiency by offering high-performing cutting efficiency combined with a dual pump mechanism and surgeon comfort by focusing on ergonomic improvements at every interaction point, which potentially reduces physical fatigue during surgery.3-6 Additionally, attendees will be able to participate in a Toric virtual reality simulator experience and explore the comprehensive TECNIS™ Toric II platform including TECNIS Eyhance™ Toric II IOL, TECNIS Symfony™ OptiBlue™ Toric II IOL and TECNIS Synergy™ Toric II IOL, alongside the entire TECNIS Family of intraocular lenses (IOLs).
“We are delighted to be back at ESCRS this year to showcase our broad range of ophthalmic innovations to our surgical customers.” said Erin McEachren, Regional Vice President, Europe, Middle East & Africa, Johnson & Johnson Surgical Vision. “We’re also pleased to see the tremendous focus being placed on sustainability by ESCRS, as this closely aligns with our own sustainability approach and commitment to a healthier planet.”
Sustainability at the heart
Creating a sustainable future for all is one of Johnson & Johnson Vision’s key priorities. Aaron Kendrick, Sr. Director, Value Stream Leader Vision, will be taking part in the inaugural ESCRS 2022 sustainability panel. He will share how Johnson & Johnson Vision is reinforcing sustainability targets across three distinct areas of focus: tackling climate change, reducing waste and protecting natural resources.
- We are on track to meet our global climate goal of achieving carbon neutrality by 20307 saving 48,000 tons of CO2 annually through renewable and energy efficient programs.8
- 100% of Johnson & Johnson Vision’s electricity will also come from renewable sources from this year,9 and we plan to offset CO2 emissions from electricity used at the booth.
- We are on a mission to limit landfill contribution through recycling efforts and to innovate in how we produce, transport and responsibly dispose of waste.
- Our manufacturing facility in the Netherlands has been Zero Waste to Landfill several years, and we no longer use plastic delivery pouches on European Surgical Vision orders (excludes Portugal).
- We’ve created the Johnson & Johnson Vision Booth by re-using more the 70% of previous booth materials from the last 3 years, in addition, the booth is made up of 50% recycled materials. We are also aiming to re-use up to 90% of our booth materials again post-congress as part of our commitment to limiting use of natural resources and reducing waste.
- We are preserving natural resources by exploring alternative ways to present and produce leaflets and materials, launching ‘Electronic Directions for Use’ in markets where they meet regulatory guidelines while ensuring all paper packaging is sourced from certified sustainable forests.
Other representatives from Johnson & Johnson Vision will be participating in events throughout ESCRS 22, including Raj Rajpal, Chief Medical Officer, Johnson & Johnson Vision; MK Raheja, Head of Surgical Vision R&D and Aaron Kendrick who will be participating in the ESCRS I-Novation session on Sustainability, Presbyopia and Cataract Extraction session taking place on Friday, 16 September, 8:30-15:30 CEST at MiCo Milano Convention Centre.
Driving diversity and inclusion
To further build upon our commitment to equality and inclusion, Johnson & Johnson Vision will also be hosting our inaugural women in Women in Ophthalmology networking and mentorship event during ESCRS. 25 influential women who work in the ophthalmology field will convene to discuss approaches to making the industry more accessible to women, with plans to grow as a network of mentors and mentees over the coming years.
Key scientific abstracts supported by Johnson & Johnson Vision include the following:
A complete listing is available at https://congress.escrs.org/programme/programme-overview/.
TECNIS Eyhance™ Toric II, TECNIS Synergy™ Toric II and TECNIS Toric II IOLs
- Clinical evaluation of a new Toric intraocular lens
- A Toric monofocal intraocular lens designed to extend the depth of focus
TECNIS Eyhance™ IOL & TECNIS Synergy™ IOL
- Comparison of clinical outcomes with a combination of IOLs with differing optical properties (TECNIS Eyhance™ IOL and TECNIS Synergy™ IOL)
- Comparison of clinical and patient-reported outcomes of a standard monofocal and a new monofocal intraocular lens with modified optical profile
- Functional outcomes after bench testing comparison of bilateral refractive lens exchange with an IOL
TECNIS Symfony™ OptiBlue™ IOL
- First real-world experience with a new extended depth of focus IOL with violet light blocker
Education and interactive sessions
Johnson & Johnson Vision is also hosting (and supporting through educational grants) a series of educational and interactive sessions aimed at sparking conversation and providing an opportunity to share, discuss and learn from leading experts in the field of ophthalmology. These include:
- IME Symposia - Phaco Complex Cases Symposium. Space 2. 16 September 2022, 16:00 – 17:00
- EuroTimes Satellite Symposium: Lock-in Visual Performance with Toric IOLs. Space 4 Room. 17 September 2022, 13:00 – 13:45
- IME Symposium – Presbyopia IOLs Space 2. 17 September 2022, 16:00 – 17:00
- IME Symposium - Advancements in Lenticule Extraction Technology. Space 2. 18 September 2022, 09:30 – 10:30
- EuroTimes Satellite Symposium: Advancements in Refractive Surgery. Brown 2 Room. 18 September 2022, 13:00 – 13:45
- Sustainability Index for Disposables in Cataract Surgery (SIDICS). MiCo Suite 1. 19 September 2022, 14:14 – 17:00
About Johnson & Johnson Vision: Surgical Vision*
At Johnson & Johnson Vision: Surgical Vision, part of Johnson & Johnson MedTech, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.
© Johnson & Johnson Medical Ltd 2022. All rights reserved.
*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Medical Ltd, and the affiliates of both.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
✝ Refractive lens exchange is not an approved indication for TECNIS Eyhance and TECNIS Synergy IOLs in the US.
1. DOF2021OTH4006 R&D Memo – Design Intent for VERITAS Vision System
2. Z370584 VERITAS Operator Manual Rev E. page 1-6, 1-8, 1-9, 3-7
3. DOF2021OTH4005 VERITAS Vision System Features
4. Honavar SG (2017) Head up, heels down, posture perfect: Ergonomics for an ophthalmologist. Indian J Ophthalmol 65 (8: 647-650).
5. Soueid A, Oudit D, Thiagarajah S, Laitung G (2010) The pain of surgery: pain experienced by surgeons while operating. Int J Surg 8 (2): 118-120.
6. DOF2021OTH4004 VERITAS foot pedal ergonomic improvements
7. https://www.jnj.com/global-environmental-health/climate-and-energy. Last accessed July 2022
8. JJV Data on File 2021. Data Substantiation for Energy Efficiency and Renewable Energy Projects at US and Ireland ACUVUE™ Contact Lens Manufacturing Facilities
9. https://www.jjvision.com/corporate-social-responsibility. Last accessed July 2022.
For Healthcare Professionals Only. Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any question.
INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS SYNERGY™ IOLWITH TECNIS SIMPLICITY® DELIVERY SYSTEM, MODEL DFR00VAND TECNIS SYNERGY™ TORIC II IOLWITH TECNIS SIMPLICITY® DELIVERY SYSTEM, MODELS DFW150, DFW225, DFW300, DFW375
INDICATIONS: The TECNIS Simplicity® Delivery System is used to fold and assist in inserting the TECNIS Synergy™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS Simplicity® Delivery System is used to fold and assist in inserting the TECNIS Synergy™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only. WARNINGS: Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear. Rotation of the TECNIS Synergy™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. PRECAUTIONS: Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Synergy™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Synergy™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Synergy™ Toric II IOL for implantation, including preoperative keratometric cylinder(magnitude and axis), incision location, the surgeon’s estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The effectiveness of TECNIS Synergy™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Synergy™ and TECNIS Synergy™ Toric II IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information.